Asset profile
BSI-045B
Monoclonal antibody
Evidence outlook · no controlled comparison
ADAMANT (NCT05932654) · Atopic Dermatitis
The lead study is single-arm or otherwise uncontrolled, so it produced no formal comparison against a control. This tier describes the design, not an outcome.
ADAMANT (NCT05932654): The study treated 22 participants in one open-label, non-randomized arm without a placebo or active comparator. Its clinical primary efficacy endpoint was reported for 17 participants, but there was no controlled comparison or formal primary endpoint test, so the favorable response rate provides limited evidence of efficacy.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
66 competitors in this universe: 0 direct rivals (same mechanism and indication), 6 same-class, 60 same-indication; 39 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| BSI-045B: this drug | Phase 2 | Monoclonal antibody | TSLP | ||
| Tezepelumab (Tezspire) | Approved | Monoclonal antibody | TSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizing | ||
| Tezepelumab (APFS) | Approved | Monoclonal antibody | TSLP | ||
| CM326 | Phase 3 | Monoclonal antibody | TSLP | ||
| GSK5784283 | Phase 3 | Monoclonal antibody | TSLP | ||
| AZD8630 | Phase 2 | — | TSLP | ||
| WIN378 | Phase 2 | Monoclonal antibody | TSLP | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | ||
| Difamilast (Moizerto / Adquey) | Approved | Small molecule | PDE4 | ||
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | ||
| Lebrikizumab (Ebglyss) | Approved | Monoclonal antibody | IL-13 | ||
| Nemolizumab (Nemluvio) | Approved | Monoclonal antibody | IL-31 receptor A | ||
| Roflumilast (Zoryve) | Approved | Small molecule | PDE4 | ||
| Ruxolitinib | Approved | Small molecule | JAK1/2 |
…and 51 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.